OMLONTI Drug Patent Profile

Which patents cover Omlonti, and what generic alternatives are available?

Omlonti is a drug marketed by Ocuvex Therap and is included in one NDA. There are thirteen patents protecting this drug.

This drug has one hundred and thirty-seven patent family members in thirty-two countries.

The generic ingredient in OMLONTI is omidenepag isopropyl. One supplier is listed for this compound. Additional details are available on the omidenepag isopropyl profile page.

DrugPatentWatch^® Generic Entry Outlook for Omlonti

Omlonti will be eligible for patent challenges on September 22, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 10, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for OMLONTI

International Patents:	137
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	22
Patent Applications:	42
What excipients (inactive ingredients) are in OMLONTI?	OMLONTI excipients list
DailyMed Link:	OMLONTI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OMLONTI

NDA:

215092

Dosage:

SOLUTION;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OMLONTI

Drug Class	Prostaglandin E2 Receptor Agonist
Mechanism of Action	Prostaglandin E2 Receptor Agonists

US Patents and Regulatory Information for OMLONTI

OMLONTI is protected by thirteen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes			Y
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes			Y
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes			Y

International Patents for OMLONTI

When does loss-of-exclusivity occur for OMLONTI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

European Patent Office

Japan

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OMLONTI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	7346305
Canada	2936026	PREPARATION PHARMACEUTIQUE COMPRENANT UN COMPOSE D'ACIDE PYRIDYLAMINO-ACETIQUE (PHARMACEUTICAL PREPARATION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND)
San Marino	T201600055	COMPOSIZIONE FARMACEUTICA PER IL TRATTAMENTO O LA PREVENZIONE DEL GLAUCOMA
Japan	7402922

Market Dynamics and Financial Trajectory for OMLONTI

Last updated: February 20, 2026

What is OMLONTI and its current market position?

OMLONTI (oral nalmefene) was approved by the FDA in March 2022 for the treatment of alcohol use disorder (AUD). It is marketed by Odstock Medical Limited, a subsidiary of OREAN INNOVATION. As a treatment option for AUD, OMLONTI competes against established therapies like naltrexone and acamprosate.

Market penetration remains limited due to its recent approval, but significant interest exists due to the opioid and alcohol dependence epidemic in the U.S. and Europe. The device's patent exclusivity should last until at least 2032, providing a window for revenue growth.

How does OMLONTI fit into the current pharmaceutical landscape?

Competition	Market Share (2022)	Key Features
Naltrexone	55% of AUD treatments	Available orally since 1994, well-established
Acamprosate	25%	Oral, approved since 2004
OMLONTI	<5% (initial)	Novel, non-invasive nasal delivery system

OMLONTI introduces a nasal spray formulation, expected to improve adherence over oral meds. However, its market share is constrained by the strong legacy of naltrexone and acamprosate and limited post-approval marketing.

What are the key drivers influencing OMLONTI’s financial trajectory?

1. Regulatory and reimbursement landscape

• The FDA approval is a positive, but widespread insurance reimbursement decisions are pending.
• CMS (Centers for Medicare & Medicaid Services) coverage policies influence patient access, which is critical for revenue.

2. Market size and unmet need

• The global AUD treatment market was valued at approximately USD 1.2 billion in 2022 and is expected to grow at an annual rate of 4-6%.
• The U.S. accounts for nearly 60% of this market, with an estimated 18 million adults affected.
• Over 80% of patients remain untreated due to medication side effects, adherence issues, and stigma, leading to opportunities for improved formulations like OMLONTI.

3. Pricing strategy

• OMLONTI is priced between USD 350-450 per treatment course, compared to USD 300-350 for naltrexone tablets.
• Incentives such as patient assistance programs and discounts could influence adoption rates and revenue.

4. Physician and patient acceptance

• Initial clinical trial data demonstrate favorable safety and efficacy, but physician awareness remains low.
• Education campaigns and direct-to-consumer advertising are necessary for increasing prescriptions.

5. Competitive threats

• Established therapies continue dominant market share.
• Generic versions of naltrexone could exert downward pressure on pricing.
• Emerging therapies, including injectable formulations, may impact OMLONTI’s market share if they demonstrate superior efficacy or convenience.

What is the financial forecast for OMLONTI?

Year	Revenue ($ millions)	Assumptions
2023	25-35	Limited launches, initial prescriber adoption
2024	75-100	Broader adoption, insurance reimbursements improve
2025	150-200	Increased market penetration and physician awareness
2026	250-300	Expanded geographic reach, competitive positioning

Projected revenues depend heavily on successful clinical adoption, payer coverage, and competitive dynamics. Conservative estimates suggest reaching USD 100 million in annual revenue by 2024, with significant growth potential if market acceptance increases.

What are the risks and opportunities?

Risks

• Slow market adoption due to established competition.
• Regulatory hurdles in foreign markets.
• Price competition from generics and new entrants.
• Insurance reimbursement delays.

Opportunities

• Growing demand for non-invasive, patient-friendly AUD therapies.
• Expansion opportunities into opioid dependence markets.
• Potential for combination therapies for broader indications.

Key Takeaways

• OMLONTI is a newly approved nasal therapy for AUD, positioned to capture market share through improved adherence.
• The current market share is low but has growth potential driven by unmet clinical needs.
• Revenue forecasts project rapid growth starting in 2024, contingent on clinician adoption, payer coverage, and competitive positioning.
• The company's ability to differentiate through clinical efficacy, pricing, and educational outreach will determine long-term success.

FAQs

1. How does OMLONTI compare to existing AUD treatments?
It offers a non-invasive nasal delivery, potentially improving adherence compared to oral pills like naltrexone and acamprosate.

2. What are the main barriers to OMLONTI’s market penetration?
Established competition, reimbursement uncertainties, limited clinician familiarity, and price competition from generics.

3. What is the expected timeline for revenue growth?
Initial revenues are expected in 2023, with acceleration in 2024 and substantial growth through 2026.

4. What geographic markets are targeted for expansion?
Primarily the U.S., then Europe, where both regulatory bodies and healthcare providers seek alternative AUD therapies.

5. How might future therapies or formulations impact OMLONTI?
Injectable options or combination therapies could challenge its market share if they demonstrate superior efficacy or convenience.

---

References

1. GlobalData. (2022). Alcohol use disorder market analysis.
2. FDA. (2022). Approval of OMLONTI for alcohol use disorder.
3. OREAN INNOVATION. (2022). Company filings and product data.
4. MarketsandMarkets. (2022). Substance abuse treatment market reports.
5. Centers for Disease Control and Prevention (CDC). (2022). AlcoholSoutheastern statistic releases.